Core Viewpoint - TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with a price target of $8 following the FDA approval of Cardamyst nasal spray for treating acute symptomatic episodes of paroxysmal supraventricular tachycardia in adults [1] Group 1: FDA Approval and Product Details - Cardamyst nasal spray received FDA approval for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults [1] - The product label is noted to be clean, with no market-limiting warnings or monitoring requirements [1] - Cardamyst is expected to be available in retail pharmacies in Q1 of 2026, with a wholesale acquisition cost of $1,649 [1]

Core Insights - Milestone Pharmaceuticals (NASDAQ:MIST) is currently viewed as a promising investment opportunity, with analysts at Jefferies raising the price target from $1 to $2, maintaining a Hold rating [1][2]. Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for self-administration by patients with episodic heart conditions [3]. Product Development and Sales Prospects - The price target increase is attributed to the company's confidence in its upcoming PDUFA, with a product launch scheduled for early next year [2]. - The company anticipates that the first quarter of next year will mark the beginning of significant sales, supported by the deployment of 60 representatives targeting up to 15,000 high-volume prescribers [2]. - Milestone is developing Etripamil, a nasal-administered, short-acting calcium channel blocker aimed at treating paroxysmal supraventricular tachycardia (PSVT) [2].

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index dropping over 250 points, down 0.60% to 44,382.58, while the NASDAQ rose slightly by 0.06% to 20,643.06, and the S&P 500 fell 0.23% to 6,266.23 [1] - European shares were lower, with the eurozone's STOXX 600 dipping 1.07%, Spain's IBEX 35 Index falling 0.99%, London's FTSE 100 down 0.47%, Germany's DAX 40 slipping 0.81%, and France's CAC 40 declining 0.94% [5] - Asian markets closed mixed, with Japan's Nikkei down 0.19%, Hong Kong's Hang Seng up 0.46%, China's Shanghai Composite gaining 0.01%, and India's BSE Sensex falling 0.83% [6] Company Earnings - WD-40 Co. (WDFC) reported better-than-expected earnings for its third quarter, although sales missed estimates. The company raised its FY2025 EPS guidance but narrowed its sales forecast [2] Stock Movements - MiNK Therapeutics, Inc. (INKT) shares surged 526% to $48.40 following a publication in Oncogene [8] - Ruanyun Edai Technology Inc. (RYET) shares increased by 19% to $18.37 after signing a strategic partnership with Confucius Institute at Prince Sultan University [8] - Signing Day Sports, Inc. (SGN) shares rose 98% to $2.4350 due to advancements in its business combination with One BlockchAIn [8] - Milestone Pharmaceuticals Inc. (MIST) shares dropped 41% to $1.5050 after announcing a public offering [8] - Federal Agricultural Mortgage Corporation (AGM) shares fell 11% to $175.20 following the announcement of the departure of its Chief Financial Officer [8] - TransMedics Group, Inc. (TMDX) shares decreased by 10% to $112.93 [8] Commodities - In commodity news, oil prices increased by 2.6% to $68.28, gold rose by 1.5% to $3,375.80, silver gained 4.1% to $38.830, while copper fell by 0.9% to $5.5425 [4]

Core Viewpoint - Milestone Pharmaceuticals has submitted a response to the FDA's Complete Response Letter regarding its New Drug Application for CARDAMYST™ (etripamil) nasal spray, aimed at treating acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults, with a new PDUFA date expected within the year [1][2]. Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative cardiovascular solutions to enhance the lives of individuals with complex heart conditions [4]. - The company emphasizes understanding unmet patient needs and improving patient experiences through new treatment approaches that allow for self-management [4]. Product Information - Etripamil is the lead investigational product of Milestone, designed as a novel calcium channel blocker nasal spray for the rapid treatment of symptomatic episodes of PSVT and atrial fibrillation with rapid ventricular response (AFib-RVR) [3]. - If approved, CARDAMYST™ will be the first self-administered therapy for the rapid termination of PSVT episodes, providing patients with greater control over their condition [2][3]. Regulatory Interaction - A recent Type A meeting with the FDA was deemed productive, providing necessary guidance for the resubmission of the NDA [2]. - The FDA's acceptance of the response and the determination of the new PDUFA date will occur within the next thirty days, with a review period expected to be between 2 to 6 months from resubmission [1].

Core Viewpoint - Milestone Pharmaceuticals (MIST) received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray, intended for treating paroxysmal supraventricular tachycardia (PSVT) [1][2] Regulatory Issues - The CRL does not raise concerns about the clinical safety or efficacy of etripamil but highlights two Chemistry, Manufacturing, and Controls (CMC) issues that need to be resolved before approval [2][11] - The first issue involves nitrosamine impurities, with the FDA requesting additional data based on new draft guidance issued after MIST's NDA submission [3] - The second issue relates to a facility inspection involved in the drug's release testing, which underwent a change in ownership during the NDA review, necessitating a compliance evaluation [4] Market Reaction - Following the CRL issuance, MIST's shares fell by 66.2%, with a year-to-date loss of 67.8%, contrasting with the industry's growth of 2.2% [2][7] - Analysts remain cautiously optimistic about the drug's prospects, suggesting a potential commercial launch in 2026, delayed from the original expectation of mid-2025 [8][11] Company Response and Financial Position - MIST has expressed its intent to request a Type A meeting with the FDA to clarify the path forward and is committed to addressing the outstanding issues [9] - As of December 31, 2024, MIST reported $69.7 million in cash and short-term investments, providing a runway for ongoing development efforts, although additional capital may be needed if delays continue [10] Investor Perspective - The CRL is viewed as a temporary obstacle rather than a fundamental rejection of CARDAMYST's therapeutic potential, with the absence of clinical concerns being a positive indicator for eventual approval [11]